Adma Biologics (ADMA) Cash from Operations (2011 - 2025)

Adma Biologics' Cash from Operations history runs 13 years deep, the most recent figure standing at 35639000.0 for Q4 2025.

• Quarterly Cash from Operations fell 29.03% year-over-year to 35639000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 50396000.0 (down 57.53% YoY) and the FY2025 annual result came in at 50396000.0, down 57.53% from the prior year.
• Cash from Operations was 35639000.0 for Q4 2025 at Adma Biologics, up from 13293000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 50216000.0 in Q4 2024 and bottomed at 33465250.0 in Q4 2021.
• A 5-year average of 299550.0 and a median of 6719029.0 in 2022 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2024 — Cash from Operations soared 853.36% — and 2025, when it tumbled 787.06%.
• Adma Biologics' Cash from Operations stood at 33465250.0 in 2021, then soared by 77.95% to 7379058.0 in 2022, then soared by 338.47% to 17597000.0 in 2023, then surged by 185.37% to 50216000.0 in 2024, then slipped by 29.03% to 35639000.0 in 2025.
• Business Quant data shows ADMA's Cash from Operations at 35639000.0 in Q4 2025, 13293000.0 in Q3 2025, and 21139000.0 in Q2 2025.